Company Overview and News

60
When a work emergency strikes, this tool will get you out of bed

2018-04-19 sfgate
As the corporate world reckons with an always-on work culture, some of the world’s biggest companies are turning to a tool made by a San Francisco startup that automatically alerts employees to issues round-the-clock.
ALL GJT NOW ALL.PRB ALL.PRC SPLS NFLX ALL.PRA ALL.PRF ALL.PRG ALL.PRD ALL.PRE

62
When a Work Emergency Strikes, This Tool Will Get You Out of Bed - Bloomberg

2018-04-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
GJT NOW ALL.PRB ALL.PRC SPLS NFLX ALL.PRA ALL.PRF ALL.PRG ALL.PRD ALL.PRE ALL GPS

191
You Are The Best Screen

2018-03-27 seekingalpha
I will warn you, though, that making investment decisions exclusively from screening can put your investments in peril.
BDX AAPL SPLS

25
Who’s Going to Move Into the Hundreds of Empty Toys ‘R’ Us Stores? - Bloomberg

2018-03-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
KIM.PRI VNO.PRICL DB VNO.WI VNORP UE.WI KIM.PRM KIM.PRL KIM.PRK KIM.PRJ CSGP KIM VNO.PRH VNO.PRK VNO.PRF VNO.PRL VNO.PRM VNO SPLS UE ROST TGT SPG.PRJ SPG VNO.PRG VNO.PRI

127
Amazon looks to secure office-supply dominance with new credit card

2018-03-13 japantimes.co.jp
NEW YORK/SEATTLE – Amazon.com Inc. is planning to offer a credit card to U.S. small-business customers, according to people with knowledge of the matter, furthering its push to supply companies with everything from reams of paper to factory parts.
COF.PRG COF.PRH C.WSA COF.WS COF.PRP COF-D COF-C C.WS.B COF-F ODP C.WS.A C.PRP C.PRU COF.PRC COF.PRD COF.PRF C.PRS COF-P C C.PRL C.PRJ C.PRK SPLS COF C.PRG SYF C.PRC C.PRPCL CGBBW

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

20h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to SPLS / Staples, Inc. on message board site Silicon Investor.

News for Staples Stock owners. Office Product Stocks - ODP/SPLS/OMX/VKNG/CEXP/OFIS/BOP
Staples (SPLS) Staples spls
CUSIP: 855030102